期刊
ENEURO
卷 5, 期 5, 页码 -出版社
SOC NEUROSCIENCE
DOI: 10.1523/ENEURO.0239-18.2018
关键词
Astrocyte; c-Fos GPCR; lipid mediator; neuroinflammation; S1P
资金
- NIH [DA019674, NS084398, NS103940]
- Novartis
- Uehara Memorial Foundation
- Kanae Foundation for the Promotion of Medical Science
- Mochida Memorial Foundation for Medical and Pharmaceutical Research
- Human Frontier Science Program
- Medical Scientist Training Program at University of California San Diego [T32GM007752]
- Pharmacology Training Grant at University of California San Diego [T32GM007752]
Astrocytes have prominent roles in central nervous system (CNS) function and disease, with subpopulations defined primarily by morphologies and molecular markers often determined in cell culture. Here, we identify an in vivo astrocyte subpopulation termed immediate-early astrocytes (ieAstrocytes) that is defined by functional c-Fos activation during CNS disease development. An unbiased screen for CNS cells showing c-Fos activation during experimental autoimmune encephalomyelitis (EAE), a mouse model for multiple sclerosis (MS), was developed by using inducible, TetTag c-Fos reporter mice that label activated cells with a temporally stable, nuclear green fluorescent protein (GFP). Four-dimensional (3D over time) c-Fos activation maps in the spinal cord were produced by combining tissue clearing (iDISCO) and confocal microscopy that identified onset and expansion of GFP(+) cell populations during EAE. More than 95% of the GFP(+) cells showed glial fibrillary acidic protein (GFAP) immunoreactivity-in contrast to absent or rare labeling of neurons, microglia, and infiltrating immune cells-which constituted ieAstrocytes that linearly increased in number with progression of EAE. ieAstrocyte formation was reduced by either astrocyte-specific genetic removal of sphingosine 1-phosphate receptor 1 (S1P(1)) or pharmacological inhibition by fingolimod (FTY720), an FDA-approved MS medicine that can functionally antagonize S1P(1). ieAstrocytes thus represent a functionally defined subset of disease-linked astrocytes that are the first and predominant CNS cell population activated during EAE, and that track with disease severity in vivo. Their reduction by a disease-modifying agent supports their therapeutic relevance to MS and potentially other neuroinflammatory and neurodegenerative diseases.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据